ORIC,ELVN Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: RCUS IDYA TNGX NUVL CGON KYMR RYTM BMRN INCY KRYS

| Held by: XBI VTI IWM VXF IWN IBB SCHA DFAS FESM DFMC

Index	RUT
Market Cap	1.12B
Enterprise Value	844.53M
Income	-135.21M
Sales	0.00M
Book/sh	4.02
Cash/sh	2.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	104
IPO	Apr 24, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.70
P/C	3.98
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.33
Current Ratio	16.33
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.43
EPS next Y	-1.61
EPS next Q	-0.36
EPS this Y	0.14%
EPS next Y	-9.57%
EPS next 5Y	-4.83%
EPS past 3/5Y	13.10% 15.18%
Sales past 3/5Y	- -
EPS Y/Y TTM	23.91%
Sales Y/Y TTM	-
EPS Q/Q	19.76%
Sales Q/Q	-
Earnings	May 04 AMC
EPS/Sales Surpr.	-6.02% -

Insider Own	39.53%
Insider Trans	-0.14%
Inst Own	77.30%
Inst Trans	-1.36%
ROA	-39.79%
ROE	-42.57%
ROIC	-32.54%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	11.75%
SMA50	20.43%
SMA200	1.67%
Trades

Shs Outstand	103.49M
Shs Float	62.59M
Short Float	35.32%
Short Ratio	13.45
Short Interest	22.11M
52W High	14.93 -27.33%
52W Low	7.23 50.07%
Volatility	7.46% 6.89%
ATR (14)	0.66
RSI (14)	64.98
Beta	1.02
Rel Volume	0.64
Avg Volume	1.64M
Volume	1,054,524

Perf Week	-6.79%
Perf Month	35.63%
Perf Quarter	4.53%
Perf Half Y	25.00%
Perf YTD	32.64%
Perf Year	-5.24%
Perf 3Y	36.65%
Perf 5Y	-41.57%
Perf 10Y	-
Recom	1.07
Target Price	20.29
Prev Close	10.94
Price	10.85
Change	-0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-12-26	Resumed	Stifel	Buy	$14
May-15-26	Upgrade	Goldman	Neutral → Buy	$15
Jan-07-26	Initiated	Piper Sandler	Overweight	$22
Nov-20-25	Initiated	Evercore ISI	Outperform	$25
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-04-25	Resumed	Guggenheim	Buy	$18
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$15
Oct-31-24	Initiated	Wells Fargo	Overweight	$20
Sep-06-24	Initiated	Stifel	Buy	$20
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform	$8
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$16
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy	$15
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform	$14
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral	$22 → $7

Show Previous Ratings

Jul-02-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.89% -6.27%
Jun-05-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.48%
May-27-26 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-04-26 04:05PM	ORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates (GlobeNewswire)
May-01-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Apr-17-26 04:05PM	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +5.08%
Apr-03-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:20AM	Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM (BioPharma Dive) +18.93%
Apr-01-26 04:05PM	Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations (The Wall Street Journal) -41.00%
Mar-31-26 04:05PM	ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile (GlobeNewswire)
Mar-27-26 08:30AM	ORIC Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC (GlobeNewswire)
Mar-17-26 05:01PM	ORIC Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -10.02%
Mar-10-26 10:38AM	Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained (24/7 Wall St.) +8.07%
Mar-09-26 09:55AM	After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright (Zacks) -15.03%
Mar-06-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:16AM	Loading…
Mar-01-26 04:16AM	Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs (MarketBeat)
Feb-26-26 09:55AM	Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade (Zacks)
Feb-25-26 10:55AM	Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright (TipRanks)
Feb-23-26 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates (GlobeNewswire) +5.40% +14.60%
Feb-14-26 02:04PM	Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25 (MarketBeat)
Feb-06-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-26 04:01PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.13%
Jan-21-26 05:59AM	Piper Sandler Puts its Weight Behind 2 Strong Buy Cancer Stocks (TipRanks) +5.42%
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire) +10.95%
Jan-12-26 08:30AM	ORIC Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones (GlobeNewswire)
Jan-06-26 04:05PM	ORIC Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.63%
Dec-15-25 11:11PM	ORIC Pharmaceuticals (ORIC) Surges as Intriguing ESMO Asia Data for Enozertinib Prompts Wells Fargo to Assign Higher Value (Insider Monkey)
Dec-05-25 08:00PM	ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:00AM	Loading…
01:00AM	ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-04-25 09:45PM	ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-03-25 04:01PM	ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-01-25 08:00AM	ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 (GlobeNewswire) -6.14%
Nov-24-25 04:05PM	ORIC Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-18-25 12:00PM	Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-25 04:10PM	ORIC Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates (GlobeNewswire)
04:05PM	ORIC Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety (GlobeNewswire)
Nov-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 04:00PM	ORIC Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor (GlobeNewswire)
Nov-04-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 08:30AM	ORIC Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors (GlobeNewswire)
Oct-22-25 09:24AM	BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now? (Zacks)
Sep-17-25 01:45PM	Oric Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-05-25 04:05PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-25 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer (GlobeNewswire)
Aug-12-25 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates (GlobeNewswire)
Aug-01-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 09:55AM	Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Jul-11-25 12:00PM	Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy? (Zacks)
Jul-03-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-19-25 12:00PM	All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy (Zacks)
09:55AM	Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect? (Zacks)
Jun-13-25 12:00PM	What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now? (Zacks)
11:30AM	JPMorgan biotech/pharma analysts hold analyst/industry conference call (TipRanks)
Jun-06-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79%
Jun-02-25 09:55AM	Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know (Zacks)
May-29-25 11:53AM	ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study (Zacks) +33.50%
12:09AM	ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials (Insider Monkey)
May-28-25 04:05PM	ORIC Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC (GlobeNewswire)
04:05PM	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing (GlobeNewswire)
May-27-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.98%
08:00AM	ORIC Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC (GlobeNewswire)
May-05-25 04:05PM	ORIC Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates (GlobeNewswire) -11.58%
May-02-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 04:30PM	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +11.10%
Apr-22-25 09:15AM	ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech (Seeking Alpha) +7.19%
07:30AM	ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans (Seeking Alpha)
Apr-16-25 11:09AM	Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -6.94%
Apr-04-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.22% -5.94%
Mar-31-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.12%
Mar-25-25 04:30PM	ORIC Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -8.41% -13.33%
Mar-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-25-25 04:15PM	ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones (GlobeNewswire) +6.88%
Feb-18-25 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates (GlobeNewswire) -6.10%
Feb-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.33%
Jan-27-25 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.85%
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire) +9.69%
Jan-14-25 08:35AM	Oric Pharmaceuticals announces clinical supply agreement with Janssen (TipRanks) +15.23%
Jan-13-25 08:05AM	ORIC Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones (GlobeNewswire) +8.04%
08:00AM	ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations (GlobeNewswire)
Jan-06-25 04:15PM	ORIC Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.82%
Jan-03-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 04:05PM	ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
Nov-04-24 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	ORIC Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 04:15PM	ORIC Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-04-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-17-24 12:00PM	OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration (PR Newswire)
Sep-14-24 05:35PM	ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-24 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.04%
Aug-12-24 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates (GlobeNewswire) +6.76%
Aug-05-24 04:15PM	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs (GlobeNewswire) -8.65%
Aug-02-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.48%
Jul-17-24 11:20AM	ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ (Zacks) -7.01%
Jul-16-24 04:59PM	ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer (GlobeNewswire)

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

FounderDr. Richard A. Heyman Ph.D.

M.D.Dr. Jacob M. Chacko M.B.A.

M.B.A.Mr. Dominic G. Piscitelli CPA

M.S.Dr. Pratik S. Multani M.D.

M.D.Dr. Charles L. Sawyers B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heyman Richard A.	Director	Jul 06 '26	Sale	12.00	300	3,600	212,772	Jul 08 04:35 PM
Richard A, Heyman	Director	Jul 06 '26	Proposed Sale	12.00	7,000	84,000		Jul 06 04:27 PM
Richard A, Heyman	Director	Jul 06 '26	Proposed Sale	12.00	6,400	76,800		Jul 06 04:27 PM
Piscitelli Dominic	Chief Financial Officer	Feb 24 '26	Option Exercise	4.36	52,000	226,720	120,148	Feb 26 04:47 PM
Piscitelli Dominic	Chief Financial Officer	Feb 24 '26	Sale	13.51	52,000	702,686	68,148	Feb 26 04:47 PM
Dominic Piscitelli	Officer	Feb 24 '26	Proposed Sale	13.50	52,000	702,000		Feb 24 04:08 PM
Heyman Richard A.	Director	Jan 16 '26	Sale	12.00	3,500	42,016	41,800	Jan 20 07:19 PM
Heyman Richard A.	Director	Jan 16 '26	Sale	12.00	3,200	38,415	213,072	Jan 20 07:19 PM
Richard A, Heyman	Director	Jan 16 '26	Proposed Sale	12.00	6,400	76,800		Jan 16 04:57 PM
Richard A, Heyman	Director	Jan 16 '26	Proposed Sale	12.00	7,000	84,000		Jan 16 04:43 PM
Multani Pratik S	Chief Medical Officer	Dec 15 '25	Option Exercise	0.00	29,333	0	78,869	Dec 17 07:21 PM
Multani Pratik S	Chief Medical Officer	Dec 16 '25	Sale	9.06	10,720	97,129	68,149	Dec 17 07:21 PM
Piscitelli Dominic	Chief Financial Officer	Dec 15 '25	Option Exercise	0.00	29,333	0	78,868	Dec 17 07:19 PM
Piscitelli Dominic	Chief Financial Officer	Dec 16 '25	Sale	9.06	10,720	97,127	68,148	Dec 17 07:19 PM
Chacko Jacob	PRESIDENT AND CEO	Dec 15 '25	Option Exercise	0.00	83,666	0	615,085	Dec 17 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Dec 16 '25	Sale	9.06	33,374	302,368	581,711	Dec 17 07:18 PM
Piscitelli Dominic	Officer	Dec 16 '25	Proposed Sale	9.06	10,720	97,128		Dec 16 09:46 PM
Multani Pratik S	Officer	Dec 16 '25	Proposed Sale	9.06	10,720	97,129		Dec 16 09:44 PM
Chacko Jacob	Officer	Dec 16 '25	Proposed Sale	9.06	33,374	302,370		Dec 16 09:42 PM
Kunkel Lori Anne	Director	Dec 08 '25	Option Exercise	7.90	10,000	79,000	84,200	Dec 09 05:35 PM
Kunkel Lori Anne	Director	Dec 04 '25	Option Exercise	3.75	5,534	20,752	74,200	Dec 05 05:47 PM
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Option Exercise	4.36	11,000	47,960	59,317	Oct 08 05:37 PM
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Sale	14.52	11,000	159,719	48,317	Oct 08 05:37 PM
Chacko Jacob	PRESIDENT AND CEO	Oct 06 '25	Sale	12.32	37,461	461,520	531,419	Oct 08 05:35 PM
Dominic Piscitelli	Officer	Oct 06 '25	Proposed Sale	14.50	50,000	725,000		Oct 06 04:22 PM
Heyman Richard A.	Director	Oct 03 '25	Option Exercise	1.69	32,800	55,591	45,300	Oct 03 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Oct 01 '25	Sale	12.05	53,001	638,805	568,880	Oct 02 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Sep 30 '25	Sale	12.01	34,538	414,750	621,881	Oct 02 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Sep 22 '25	Sale	10.80	125,000	1,349,938	656,419	Sep 24 04:30 PM
Jacob Chacko	Director	Sep 22 '25	Proposed Sale	10.50	250,000	2,625,000		Sep 22 04:31 PM

ELVN Enliven Therapeutics Inc daily Stock Chart

Peers: ERAS IDYA TNGX CGON KYMR NUVL BMRN INCY RYTM AXSM

| Held by: VTI IWM IBB IWO VXF SCHA XPH DFAS IHE VTWO

Index	RUT
Market Cap	3.65B
Enterprise Value	3.20B
Income	-98.78M
Sales	0.00M
Book/sh	7.45
Cash/sh	6.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	60
IPO	Mar 12, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.86
P/C	8.07
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	40.32
Current Ratio	40.32
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.66
EPS next Y	-2.31
EPS next Q	-0.39
EPS this Y	6.59%
EPS next Y	-35.30%
EPS next 5Y	-16.86%
EPS past 3/5Y	46.65% 33.56%
Sales past 3/5Y	- -
EPS Y/Y TTM	13.79%
Sales Y/Y TTM	-
EPS Q/Q	34.03%
Sales Q/Q	-
Earnings	May 07 AMC
EPS/Sales Surpr.	14.34% -

Insider Own	20.99%
Insider Trans	-9.34%
Inst Own	71.61%
Inst Trans	-0.29%
ROA	-25.74%
ROE	-26.64%
ROIC	-21.79%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.65%
SMA50	18.58%
SMA200	68.38%
Trades

Shs Outstand	60.89M
Shs Float	56.44M
Short Float	15.11%
Short Ratio	6.36
Short Interest	8.53M
52W High	52.39 -2.48%
52W Low	14.78 245.55%
Volatility	4.68% 7.05%
ATR (14)	2.78
RSI (14)	64.07
Beta	0.28
Rel Volume	0.47
Avg Volume	1.34M
Volume	623,677

Perf Week	2.55%
Perf Month	41.48%
Perf Quarter	12.06%
Perf Half Y	230.25%
Perf YTD	231.75%
Perf Year	124.28%
Perf 3Y	186.22%
Perf 5Y	77.40%
Perf 10Y	-
Recom	1.09
Target Price	65.00
Prev Close	52.18
Price	51.09
Change	-2.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-26	Initiated	Stifel	Buy	$60
May-12-26	Initiated	Guggenheim	Buy	$80
Jun-16-25	Initiated	Goldman	Buy	$37
Dec-13-24	Initiated	BTIG Research	Buy	$42
Sep-09-24	Initiated	H.C. Wainwright	Buy	$37
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Today 07:26PM	HMI Capital Pares Its Stake in AI Company nCino (Barrons.com)
Jun-15-26 04:40PM	Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) -8.17%
Jun-12-26 02:22PM	ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development (Stocktwits) +14.30%
Jun-11-26 10:39PM	Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +9.08%
04:05PM	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
10:36AM	Loading…
10:36AM	Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN) (InvestorsHub)
08:00AM	Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components (PR Newswire)
Jun-09-26 09:32AM	Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls (The Fly) +7.37%
Jun-03-26 04:05PM	Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress (PR Newswire)
May-21-26 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-12-26 09:53AM	Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML (PR Newswire) +6.85%
May-07-26 04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (PR Newswire)
Feb-25-26 04:05PM	Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (PR Newswire)
Jan-08-26 02:16PM	Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars (Benzinga) +50.29%
09:00AM	Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones (PR Newswire)
09:00AM	Loading…
Jan-07-26 09:00AM	Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development (PR Newswire)
Dec-11-25 04:21PM	Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules (PR Newswire) -6.94% -10.18%
09:00AM	Enliven Therapeutics Announces New CEO to Drive Next Phase of Development (PR Newswire)
Dec-03-25 09:55AM	Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade (Zacks)
Nov-17-25 09:55AM	Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect? (Zacks)
Nov-12-25 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire)
Sep-12-25 09:55AM	Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know (Zacks)
Sep-09-25 12:00PM	Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-27-25 09:55AM	How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41% (Zacks)
Aug-25-25 06:20PM	Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting (PR Newswire)
Aug-13-25 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (PR Newswire) +5.80%
Jul-18-25 09:55AM	Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jun-17-25 01:33PM	Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data (Insider Monkey) -5.59%
Jun-16-25 04:05PM	Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) +5.39%
Jun-13-25 09:30AM	Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +11.44%
06:10AM	Loading…
06:10AM	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
06:02AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress (PR Newswire)
May-22-25 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-17-25 12:40PM	Enliven price target lowered to $27 from $36 at JonesResearch (TipRanks)
May-14-25 04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (PR Newswire) -10.41%
09:56AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress (PR Newswire)
Apr-22-25 02:54PM	Enliven Therapeutics: Awaiting Additional Trial Data (Seeking Alpha) +10.79%
Apr-02-25 04:03PM	Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting (PR Newswire) +5.19%
Mar-13-25 04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (PR Newswire)
Feb-25-25 04:05PM	Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (PR Newswire) -5.71%
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

CEOMr. Richard A. Fair M.B.A.

Co-Founder & Head of PipelineMr. Samuel S. Kintz M.B.A.

CFO & Head of Corporate DevelopmentMr. Benjamin Hohl

Chief Medical OfficerDr. Helen Louise Collins M.D.

Co-Founder & Research FellowDr. Joseph P. Lyssikatos Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kunkel Lori Anne	Director	Jul 06 '26	Sale	50.49	10,000	504,903	41,884	Jul 08 05:15 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 22 '26	Sale	45.36	860,123	39,014,046	219,405	Jun 24 07:19 PM
OrbiMed Genesis Master Fund, L	Shareholder	Jun 22 '26	Proposed Sale	45.96	24,846	1,141,922		Jun 22 08:13 PM
OrbiMed Private Investments VI	Shareholder	Jun 22 '26	Proposed Sale	45.96	787,024	36,171,623		Jun 22 08:10 PM
The Biotech Growth Trust PLC	Shareholder	Jun 22 '26	Proposed Sale	45.96	29,385	1,350,535		Jun 22 08:08 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 17 '26	Option Exercise	2.48	6,018	14,925	57,018	Jun 22 05:13 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 17 '26	Sale	43.80	6,018	263,577	51,000	Jun 22 05:13 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jun 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Jun 22 05:11 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jun 17 '26	Sale	43.80	5,000	219,017	25,000	Jun 22 05:11 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 15 '26	Sale	45.02	281,408	12,668,988	245,728	Jun 17 07:45 PM
Hohl Benjamin	Officer	Jun 17 '26	Proposed Sale	42.55	18,054	768,198		Jun 17 04:24 PM
The Biotech Growth Trust PLC	Shareholder	Jun 15 '26	Proposed Sale	42.36	10,243	433,893		Jun 15 09:23 PM
OrbiMed Private Investments VI	Shareholder	Jun 15 '26	Proposed Sale	42.36	272,322	11,535,560		Jun 15 09:21 PM
OrbiMed Genesis Master Fund, L	Shareholder	Jun 15 '26	Proposed Sale	42.36	9,086	384,883		Jun 15 09:18 PM
Kunkel Lori Anne	Director	Jun 05 '26	Sale	34.54	10,000	345,351	51,884	Jun 09 04:49 PM
Kunkel Lori Anne	Board Member	Jun 05 '26	Proposed Sale	35.49	20,000	709,800		Jun 05 04:29 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	May 18 '26	Option Exercise	2.48	5,000	12,400	30,000	May 20 04:18 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	May 18 '26	Sale	39.79	5,000	198,971	25,000	May 20 04:18 PM
Collins Helen Louise	Officer	May 18 '26	Proposed Sale	41.34	15,000	620,100		May 18 04:28 PM
Lyssikatos Joseph P	Officer	Apr 30 '26	Proposed Sale	42.40	25,000	1,060,000		Apr 30 04:17 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Apr 21 08:40 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 17 '26	Sale	47.67	5,000	238,352	25,000	Apr 21 08:40 PM
Lyssikatos Joseph P	Officer	Mar 31 '26	Proposed Sale	36.59	25,000	914,750		Mar 31 04:29 PM
ANDREW PHILLIPS	Former Director	Mar 31 '26	Proposed Sale	38.55	26,035	1,003,610		Mar 31 04:26 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 25 '26	Option Exercise	2.48	40,000	99,200	65,000	Mar 27 04:57 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 25 '26	Sale	35.10	40,000	1,404,024	25,000	Mar 27 04:57 PM
Collins Helen Louise	Officer	Mar 25 '26	Proposed Sale	31.15	45,000	1,401,750		Mar 25 04:29 PM
Patel Anish	Officer	Mar 24 '26	Proposed Sale	30.81	100,000	3,081,000		Mar 24 04:26 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Mar 19 05:50 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 17 '26	Sale	27.76	5,000	138,800	25,000	Mar 19 05:50 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 09 '26	Option Exercise	2.48	29,871	74,080	54,871	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 10 '26	Option Exercise	2.48	10,129	25,120	35,129	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 09 '26	Sale	30.02	29,871	896,811	25,000	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 10 '26	Sale	30.19	10,129	305,827	25,000	Mar 11 05:32 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 06 '26	Sale	29.58	10,000	295,839	51,000	Mar 10 06:15 PM
Collins Helen Louise	Officer	Mar 09 '26	Proposed Sale	29.44	45,000	1,324,800		Mar 09 04:12 PM
Hohl Benjamin	Officer	Mar 06 '26	Proposed Sale	29.29	10,000	292,900		Mar 06 04:06 PM
Heyman Richard A.	Director	Feb 17 '26	Sale	26.18	1,230	32,196	22,647	Feb 19 06:38 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Feb 17 '26	Option Exercise	2.48	45,000	111,600	70,000	Feb 19 06:36 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Feb 17 '26	Sale	26.17	45,000	1,177,862	25,000	Feb 19 06:36 PM
Lyssikatos Joseph P	Officer	Feb 18 '26	Proposed Sale	26.13	75,000	1,959,750		Feb 18 04:25 PM
Kintz Samuel	Officer	Feb 17 '26	Proposed Sale	26.72	75,000	2,004,000		Feb 17 04:50 PM
Heyman Richard A.	Director	Feb 17 '26	Proposed Sale	26.72	1,230	32,866		Feb 17 04:44 PM
Collins Helen Louise	Officer	Feb 17 '26	Proposed Sale	26.72	45,000	1,202,400		Feb 17 04:40 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Feb 06 '26	Sale	29.04	5,000	145,219	740,188	Feb 10 06:12 PM
ANDREW PHILLIPS	Former Director	Feb 02 '26	Proposed Sale	28.00	21,844	611,719		Feb 02 05:38 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 20 '26	Sale	26.75	20,000	535,099	745,188	Jan 22 05:34 PM
Heyman Richard A.	Director	Jan 20 '26	Sale	26.75	1,230	32,902	23,877	Jan 22 05:33 PM
Heyman Richard A.	Director	Jan 20 '26	Proposed Sale	26.71	1,230	32,853		Jan 20 04:55 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 09 '26	Sale	27.99	48,300	1,351,762	215,011	Jan 13 05:54 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 09 '26	Sale	27.22	91,198	2,482,578	765,188	Jan 12 05:12 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 08 '26	Sale	24.05	41,302	993,436	856,386	Jan 12 05:12 PM
Heyman Richard A.	Director	Jan 08 '26	Sale	25.03	9,635	241,156	25,545	Jan 12 05:11 PM
Heyman Richard A.	Director	Jan 09 '26	Sale	25.00	4,285	107,125	25,107	Jan 12 05:11 PM
Lyssikatos Joseph P	Officer	Jan 09 '26	Proposed Sale	23.25	75,000	1,743,750		Jan 09 04:50 PM
Kintz Samuel	Officer	Jan 09 '26	Proposed Sale	23.25	75,000	1,743,750		Jan 09 04:49 PM
Patel Anish	Officer	Jan 09 '26	Proposed Sale	23.25	48,300	1,122,975		Jan 09 04:18 PM
Kintz Samuel	Officer	Jan 08 '26	Proposed Sale	15.47	82,500	1,276,275		Jan 08 04:42 PM
Lyssikatos Joseph P	Officer	Jan 08 '26	Proposed Sale	15.47	82,500	1,276,275		Jan 08 04:26 PM
Heyman Richard A.	Director	Jan 08 '26	Proposed Sale	15.47	1,620	25,061		Jan 08 04:26 PM
Heyman Richard A.	Director	Jan 08 '26	Proposed Sale	15.47	12,300	190,281		Jan 08 04:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 22 '25	Option Exercise	2.48	13,000	32,240	36,000	Dec 23 06:47 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Dec 19 '25	Sale	16.84	5,000	84,206	897,688	Dec 23 06:45 PM
Kunkel Lori Anne	Director	Dec 17 '25	Option Exercise	1.12	15,958	17,873	30,712	Dec 19 05:58 PM
Lyssikatos Joseph P	Officer	Dec 19 '25	Proposed Sale	16.68	5,000	83,400		Dec 19 04:32 PM
Kintz Samuel	Officer	Dec 17 '25	Proposed Sale	16.91	5,000	84,550		Dec 17 04:23 PM
Patel Anish	CHIEF OPERATING OFFICER	Dec 08 '25	Sale	21.02	6,663	140,073	263,311	Dec 10 05:13 PM
Patel Anish	Officer	Dec 08 '25	Proposed Sale	21.81	6,663	145,320		Dec 08 04:18 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Nov 19 '25	Sale	22.33	12,500	279,155	902,688	Nov 21 05:28 PM
Kintz Samuel	PRESIDENT AND CEO	Nov 17 '25	Sale	21.82	12,500	272,739	890,392	Nov 19 06:45 PM
Lyssikatos Joseph P	Officer	Nov 19 '25	Proposed Sale	22.59	12,500	282,375		Nov 19 04:05 PM
Kintz Samuel	Officer	Nov 17 '25	Proposed Sale	22.07	12,500	275,875		Nov 17 04:16 PM
Patel Anish	CHIEF OPERATING OFFICER	Nov 07 '25	Sale	17.40	6,667	116,034	269,974	Nov 12 05:34 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 20 '25	Sale	22.08	12,500	276,025	915,188	Oct 22 07:20 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 17 '25	Sale	21.33	12,500	266,654	902,892	Oct 21 06:13 PM
Lyssikatos Joseph P	Officer	Oct 20 '25	Proposed Sale	21.41	12,500	267,625		Oct 20 04:10 PM
Kintz Samuel	Officer	Oct 17 '25	Proposed Sale	21.75	12,500	271,875		Oct 17 04:16 PM
Patel Anish	CHIEF OPERATING OFFICER	Oct 07 '25	Sale	20.10	6,667	133,993	276,641	Oct 09 05:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 29 '25	Option Exercise	2.48	3,250	8,060	26,250	Oct 01 04:46 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 29 '25	Sale	20.40	3,250	66,291	23,000	Oct 01 04:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 26 '25	Sale	20.25	4,000	81,005	927,688	Sep 30 05:53 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 26 '25	Sale	20.06	3,700	74,228	915,392	Sep 30 05:51 PM
Hohl Benjamin	Officer	Sep 29 '25	Proposed Sale	20.01	4,500	90,045		Sep 29 05:19 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 23 '25	Sale	20.03	1,500	30,045	931,688	Sep 25 07:44 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 23 '25	Sale	20.03	2,800	56,084	919,092	Sep 25 07:42 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 19 '25	Sale	19.39	7,000	135,697	933,188	Sep 23 05:14 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 17 '25	Sale	19.09	5,000	95,473	922,892	Sep 19 07:12 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 19 '25	Sale	20.25	1,000	20,250	921,892	Sep 19 07:12 PM
Lyssikatos Joseph P	Officer	Sep 19 '25	Proposed Sale	19.93	12,500	249,125		Sep 19 05:32 PM
Kintz Samuel	Officer	Sep 17 '25	Proposed Sale	18.43	12,500	230,375		Sep 17 04:08 PM
Patel Anish	CHIEF OPERATING OFFICER	Sep 08 '25	Sale	20.24	6,667	134,957	283,308	Sep 10 08:12 PM
Patel Anish	Officer	Sep 08 '25	Proposed Sale	20.15	20,001	403,020		Sep 08 04:30 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Aug 29 05:03 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	20.63	3,250	67,039	23,000	Aug 29 05:03 PM
Hohl Benjamin	Officer	Aug 27 '25	Proposed Sale	20.32	5,250	106,680		Aug 27 04:44 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 21 '25	Sale	20.01	7,500	150,099	940,188	Aug 21 06:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 19 '25	Sale	19.62	5,000	98,118	947,688	Aug 21 06:46 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 18 '25	Sale	20.02	10,393	208,106	929,999	Aug 20 04:36 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 19 '25	Sale	20.00	590	11,800	929,409	Aug 20 04:36 PM
Lyssikatos Joseph P	Officer	Aug 19 '25	Proposed Sale	19.75	12,500	246,875		Aug 19 04:24 PM

ORIC

ORIC Pharmaceuticals Inc

ELVN

Enliven Therapeutics Inc

Upgrade your Finviz experience